Guardant Health Inc (GH) Stock Price, Quote & News

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-pow...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 855 698 8887

Fax: 888 974 4258

Website: guardanthealth.com

Address:

3100 Hanover Street, Palo Alto, United States

BEATOFtheMARKET Nov. 17 at 12:38 AM

$GEOS $GEVO $GGAL $GH $GIFI

0 · Reply

GoldenBum77 Nov. 14 at 3:01 PM

$GH Enough with the flip-flopping. This should be skyrocketing. Blood cancer detection?!? This is a modern medicine breakthrough!!

1 · Reply

GetOverHere_ Nov. 14 at 8:49 AM

$STGW $PRTS $EBAY $GH _

0 · Reply

IN0V8 Nov. 11 at 5:12 PM

$GH Opportunity Jefferies raises target price to $115 from $85

0 · Reply

Woodman7 Nov. 11 at 1:43 PM

$EXAS - took a look at the Price/Sales valuations now that we are through the 3Q reporting period. Per YF: $GH 13.3x $NTRA 13.2x $GRAL 20.0x $EXAS 4.0x

2 · Reply

MaverikIT Nov. 10 at 4:15 PM

$GH - knocking on door 'century'

0 · Reply

The1Albatross Nov. 10 at 3:17 PM

$GH Triple dig land From $16

1 · Reply

MaverikIT Nov. 10 at 3:15 PM

$ARWR $GH - nice 3 mths

0 · Reply

aristocks Nov. 10 at 2:59 PM

$GH awesome!!

0 · Reply

Gator5326 Nov. 10 at 2:05 PM

$GH “Guardant Reveal continues to redefine what’s possible in liquid biopsy for oncologists and patients, creating a new paradigm for therapy monitoring,” said Helmy Eltoukhy, Guardant Health Chairman and co-CEO. “By integrating therapy response monitoring into Guardant Reveal, we now have an end-to-end monitoring test built on the Infinity Smart Platform that simplifies clinical workflows and empowers providers to make faster, more informed decisions with just a simple blood draw.”

0 · Reply

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Nov 10, 2025, 8:05 AM EST - 6 days ago

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Nov 7, 2025, 8:00 AM EST - 9 days ago

Guardant Health to Participate in Upcoming Investor Conferences

Nov 6, 2025, 6:35 PM EST - 10 days ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 6, 2025, 8:05 AM EST - 10 days ago

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

Nov 5, 2025, 4:05 PM EST - 11 days ago

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Nov 5, 2025, 2:15 AM EST - 11 days ago

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

Nov 5, 2025, 2:15 AM EST - 11 days ago

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Nov 4, 2025, 4:39 PM EST - 12 days ago

Guardant Health Announces Proposed Public Offering of Common Stock

Nov 4, 2025, 4:38 PM EST - 12 days ago

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Oct 31, 2025, 11:09 AM EDT - 16 days ago

Guardant Health Beats Expectations: Shield, Quest, And AI Catalysts

Oct 30, 2025, 9:03 PM EDT - 17 days ago

Guardant Health: Business Continues To Gather Pace

Oct 30, 2025, 1:46 AM EDT - 18 days ago

Guardant Health, Inc. (GH) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 18 days ago

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 27, 2025, 8:05 AM EDT - 20 days ago

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Oct 26, 2025, 3:01 PM EDT - 21 days ago

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Oct 15, 2025, 4:57 PM EDT - 4 weeks ago

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Oct 9, 2025, 4:05 PM EDT - 5 weeks ago

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

Sep 29, 2025, 8:05 AM EDT - 6 weeks ago

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

Sep 24, 2025, 7:17 PM EDT - 7 weeks ago

Guardant Health, Inc. (GH) Analyst/Investor Day Transcript

Sep 24, 2025, 8:05 AM EDT - 7 weeks ago

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

DGX

Sep 15, 2025, 4:07 PM EDT - 2 months ago

Alex M. Azar II Joins Guardant Health Board of Directors

Sep 11, 2025, 8:05 AM EDT - 2 months ago

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Sep 8, 2025, 6:56 PM EDT - 2 months ago

Guardant Health, Inc. (GH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 8:05 AM EDT - 2 months ago

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Sep 4, 2025, 8:06 AM EDT - 2 months ago

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Aug 28, 2025, 4:05 PM EDT - 2 months ago

Guardant Health to Host Investor Day on September 24, 2025

Aug 26, 2025, 4:05 PM EDT - 2 months ago

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 7, 2025, 9:45 PM EDT - 3 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW EXAS ISRG LLY MASI

Aug 4, 2025, 8:06 AM EDT - 3 months ago

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

Jul 31, 2025, 4:05 PM EDT - 3 months ago

Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 31, 2025, 2:10 PM EDT - 3 months ago

Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings

Jul 31, 2025, 11:13 AM EDT - 3 months ago

Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Jul 30, 2025, 8:09 AM EDT - 3 months ago

Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+

Jul 29, 2025, 8:07 AM EDT - 3 months ago

New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer

Jul 15, 2025, 11:01 AM EDT - 4 months ago

First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test

Jul 14, 2025, 8:00 AM EDT - 4 months ago

Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

Jun 10, 2025, 7:05 AM EDT - 5 months ago

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Jun 9, 2025, 8:05 AM EDT - 5 months ago

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

Jun 3, 2025, 2:56 PM EDT - 5 months ago

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?

Jun 3, 2025, 8:05 AM EDT - 5 months ago

FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

Jun 2, 2025, 8:05 AM EDT - 5 months ago

National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

Jun 2, 2025, 7:00 AM EDT - 5 months ago

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

May 31, 2025, 8:05 AM EDT - 6 months ago

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

May 27, 2025, 5:30 PM EDT - 6 months ago

Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

May 22, 2025, 5:05 PM EDT - 6 months ago

Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting

May 21, 2025, 8:05 AM EDT - 6 months ago

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

May 20, 2025, 8:05 AM EDT - 6 months ago

Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer

May 8, 2025, 9:20 AM EDT - 6 months ago

TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year

BEATOFtheMARKET Nov. 17 at 12:38 AM

$GEOS $GEVO $GGAL $GH $GIFI

0 · Reply

GoldenBum77 Nov. 14 at 3:01 PM

$GH Enough with the flip-flopping. This should be skyrocketing. Blood cancer detection?!? This is a modern medicine breakthrough!!

1 · Reply

GetOverHere_ Nov. 14 at 8:49 AM

$STGW $PRTS $EBAY $GH _

0 · Reply

IN0V8 Nov. 11 at 5:12 PM

$GH Opportunity Jefferies raises target price to $115 from $85

0 · Reply

Woodman7 Nov. 11 at 1:43 PM

$EXAS - took a look at the Price/Sales valuations now that we are through the 3Q reporting period. Per YF: $GH 13.3x $NTRA 13.2x $GRAL 20.0x $EXAS 4.0x

2 · Reply

MaverikIT Nov. 10 at 4:15 PM

$GH - knocking on door 'century'

0 · Reply

The1Albatross Nov. 10 at 3:17 PM

$GH Triple dig land From $16

1 · Reply

MaverikIT Nov. 10 at 3:15 PM

$ARWR $GH - nice 3 mths

0 · Reply

aristocks Nov. 10 at 2:59 PM

$GH awesome!!

0 · Reply

Gator5326 Nov. 10 at 2:05 PM

0 · Reply

BEATOFtheMARKET Nov. 9 at 9:43 PM

$GEV $GFF $GFS $GGLL $GH

0 · Reply

GambleLifeAway Nov. 7 at 2:24 PM

$CAI - Objectively surpasses all of the competitors below with their tech and future capabilities, yet the price point does not reflect that. $BLLN opened at $60 yesterday and immediately shot up to $110, yet $CAI is almost back to their opening IPO price after a strong earnings call. This speaks volume to their lack of media promotion, marketing, and investor relations updates. What an awful IPO execution by $CAI. Doesn’t seem like they were ready to step up to the big dogs in NASDAQ. $BLLN $NTRA $GH $TEM

0 · Reply

TedStockwits1 Nov. 7 at 1:10 AM

$GH

1 · Reply

aristocks Nov. 6 at 7:42 PM

$GH company could be a good M&A target? Phama/Helathcare lately getting hotter.. I would not be surprise if this one get taken out! What you guys/girl think? Do your DD. Not financial advise.

1 · Reply

aristocks Nov. 6 at 7:36 PM

$GH going to 100$ Lets go!

1 · Reply

BioTechHealthX Nov. 6 at 6:11 PM

$GH DCF model shows Guardant Health trading 61.9% below fair value despite massive 2025 rally. Read this article to know more. https://biotechhealthx.com/biotech-news/why-analysts-see-guardant-health-gh-rallying-to-249/

0 · Reply

annomymous Nov. 6 at 5:48 PM

$EXAS wild price action. $GH bumps up 30% after earnings with arguably less impressive results to exacts, then they announce public offering diluting shareholders and hold their bounce. Exact bounces 10% and fades all the way back to pre q3 report. Frustrating but know what you own I guess

2 · Reply

prismmarketview Nov. 6 at 3:47 PM

(NASDAQ: $GH) #GuardantHealth's new study validates its Reveal™ blood test for early and accurate monitoring of chemotherapy response in advanced breast cancer, showing 100% sensitivity and specificity in detecting recurrence, and offering oncologists a powerful non-invasive tool for treatment decisions and disease management. https://prismmarketview.com/guardant-health-strengthens-liquid-biopsy-leadership-with-new-validation-study-on-reveal-blood-test/

0 · Reply

GambleLifeAway Nov. 6 at 3:04 PM

$CAI - Killer earnings, revolutionary pipeline, yet tanks 10% prior to the earnings call? It’s because they lack promotion and marketing, whereas $TEM and $GH blast financials and updates all across the media. The marketing and investor relations departments need kicked to the curb. They are partially responsible for investors losing millions today. This should easily be +$40.

0 · Reply

Woodman7 Nov. 6 at 12:55 PM

Source: The Motley Fool $EXAS $SPY $QQQ $GH You owe it to yourself to read this call transcript. https://share.google/ow5AhxX95c6m7acgD

0 · Reply

IN0V8 Nov. 6 at 5:19 AM

$GH Raymond James raises target price to $115 from $61

0 · Reply

Gator5326 Nov. 5 at 10:27 PM

$GH 95%! Damn. https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZ-2FtX741n0Z6WOyiD4GHhsE27lSui-2B4x8k3ZhdZ2uVnEU7yuGryHAOUz2xNrV9I2uSUqNDezDATElGEdTpb7MLxVKneGgvcfqr3NU8HubgqM48V4ZjC6iM9QrUswqWZ3fmszPWZ9tSF35rU-2FNUaiRsIA-3DF9Do_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHZE05rt08oTgQ7jC9c8KxbrYhFQyzOzoT7wjfGJH0zjX8mbKgeMLW3PfBRhs7iZM7GuQaVC1BntxFlJK85h5w2KJ5n-2BRbZ3i4nisZQA1YtMqLNfd6VLDRb5SrXdGadHguIOADSEwDLB5nFh-2B3-2B3AYHlUaAyYKeAknzoKcZJ6TnFNKcBvQcE9n-2BpDFZVLnIQsUGzewGJoxO0LahO3BTa9PrR7hD9mN7jdkt-2BvO0QMaLRlthrZy3LjrykSbCbJ2htjr9-2BJX6K3OfcxjssYc-2FHa-2F8vDFn05iOJTMdjJWYymDn-2BM-3D

0 · Reply

Market Cap	11.89B
Revenue (ttm)	739.02M
Net Income (ttm)	-436.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-59.05%
Debt to Equity Ratio	-3.14

Volume	1,732,400
Avg Vol	2,727,418
Day's Range	N/A - N/A
Shares Out	126.04M
Stochastic %K	43%
Beta	1.56
Analysts	Strong Sell
Price Target	$100.38